- Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
- Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
- Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
- Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
- Pacira to Report 2023 Financial Results on Thursday February 29, 2024
- Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
- Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
- Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
- Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Monday, Pacira Biosciences Inc (PCRX:NSQ) closed at 26.50, 4.62% above its 52-week low of 25.33, set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 27.45 |
---|---|
High | 27.86 |
Low | 26.47 |
Bid | 26.00 |
Offer | 28.49 |
Previous close | 27.21 |
Average volume | 425.87k |
---|---|
Shares outstanding | 46.52m |
Free float | 45.94m |
P/E (TTM) | 40.08 |
Market cap | 1.27bn USD |
EPS (TTM) | 0.6789 USD |
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
More ▼